AU2007212076B2 - Yeast-based vaccine for inducing an immune response - Google Patents

Yeast-based vaccine for inducing an immune response Download PDF

Info

Publication number
AU2007212076B2
AU2007212076B2 AU2007212076A AU2007212076A AU2007212076B2 AU 2007212076 B2 AU2007212076 B2 AU 2007212076B2 AU 2007212076 A AU2007212076 A AU 2007212076A AU 2007212076 A AU2007212076 A AU 2007212076A AU 2007212076 B2 AU2007212076 B2 AU 2007212076B2
Authority
AU
Australia
Prior art keywords
yeast
protein
antigen
influenza
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007212076A
Other languages
English (en)
Other versions
AU2007212076A1 (en
Inventor
Richard C. Duke
Alex Franzusoff
Aurelia Haller
Victoria Kelley Hodson
Thomas H. King
Yingnian Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlobeImmune Inc
Original Assignee
GlobeImmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlobeImmune Inc filed Critical GlobeImmune Inc
Publication of AU2007212076A1 publication Critical patent/AU2007212076A1/en
Application granted granted Critical
Publication of AU2007212076B2 publication Critical patent/AU2007212076B2/en
Priority to AU2013200249A priority Critical patent/AU2013200249A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2007212076A 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response Ceased AU2007212076B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013200249A AU2013200249A1 (en) 2006-02-02 2013-01-17 Yeast-based vaccine for inducing an immune response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
US60/765,025 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013200249A Division AU2013200249A1 (en) 2006-02-02 2013-01-17 Yeast-based vaccine for inducing an immune response

Publications (2)

Publication Number Publication Date
AU2007212076A1 AU2007212076A1 (en) 2007-08-16
AU2007212076B2 true AU2007212076B2 (en) 2012-10-18

Family

ID=38345897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007212076A Ceased AU2007212076B2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Country Status (14)

Country Link
US (2) US7736642B2 (enExample)
EP (2) EP1988919A4 (enExample)
JP (3) JP5198290B2 (enExample)
KR (2) KR20140029551A (enExample)
CN (2) CN101405026B (enExample)
AU (1) AU2007212076B2 (enExample)
BR (1) BRPI0706913A2 (enExample)
CA (1) CA2638815A1 (enExample)
IL (2) IL193196A (enExample)
IN (1) IN2014DN08830A (enExample)
MX (1) MX2008009929A (enExample)
SG (2) SG169375A1 (enExample)
TW (2) TW201412329A (enExample)
WO (1) WO2007092792A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP4914990B2 (ja) 2002-12-16 2012-04-11 グローブイミューン，インコーポレイテッド 動物を癌から守るための治療用組成物
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2007008780A2 (en) * 2005-07-11 2007-01-18 Globeimmune, Inc. Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
US20100143393A1 (en) * 2006-05-11 2010-06-10 Gale Smith Novel influenza m2 vaccines
EP2023952B1 (en) * 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
CN101687030B (zh) * 2007-02-02 2014-07-02 环球免疫公司 用于生产基于酵母的疫苗的方法
WO2008115610A1 (en) * 2007-03-19 2008-09-25 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
EP2432503A4 (en) * 2009-05-18 2013-01-23 Panacea Biotec Ltd BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
WO2012006561A2 (en) * 2010-07-08 2012-01-12 New York Medical College Influenza virus detection and diagnosis
AU2011312178B2 (en) * 2010-10-04 2016-05-12 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US9173933B2 (en) * 2010-10-15 2015-11-03 Bavarian Nordic A/S Recombinant modified vaccinia virus Ankara influenza vaccine
EP2651439B1 (en) 2010-12-17 2018-09-19 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP6169494B2 (ja) * 2011-01-31 2017-07-26 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
JP6068368B2 (ja) 2011-03-17 2017-01-25 グローブイミューン，インコーポレイテッド 酵母−ブラキュリ免疫治療組成物
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
EP2720716B1 (en) 2011-06-14 2018-03-21 Globeimmune, Inc. Immunotherapeutic compositions for the treatment or prevention of hepatitis delta virus infection
EP2721158B1 (en) * 2011-06-20 2017-05-03 University of Pittsburgh - Of the Commonwealth System of Higher Education Computationally optimized broadly reactive antigens for h1n1 influenza
CN109010809A (zh) 2011-08-17 2018-12-18 全球免疫股份有限公司 酵母-muc1免疫治疗组合物及其用途
EP2591798B1 (en) * 2011-11-09 2014-11-19 Werner Lubitz Vaccine for use in tumor immunotherapy
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
AU2013359469B2 (en) * 2012-12-10 2019-05-16 Seattle Biomedical Research Institute Cell-free biofragment compositions and related systems, devices, and methods
AU2014235120B2 (en) * 2013-03-15 2017-01-05 The Trustees Of The University Of Pennsylvania Vaccines having an antigen and interleukin-23 as an adjuvant
MX374829B (es) 2013-03-19 2025-03-06 Globeimmune Inc Composición a base de levadura para usarse para tratar cordoma.
US9782473B2 (en) 2013-03-26 2017-10-10 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
TWI654200B (zh) * 2013-08-30 2019-03-21 環球免疫公司 治療或預防結核病的組合物及方法
WO2015103602A1 (en) * 2014-01-06 2015-07-09 The Trustees Of The University Of Pennsylvania Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
EP3113759B1 (en) 2014-03-05 2021-05-12 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
CA2948803A1 (en) 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
TWI748957B (zh) 2015-08-03 2021-12-11 美商環球免疫公司 經修飾之酵母-短尾畸型（Ｂｒａｃｈｙｕｒｙ）免疫治療組合物
WO2017027568A1 (en) * 2015-08-11 2017-02-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
JP2019513021A (ja) 2016-03-24 2019-05-23 ナントセル，インコーポレイテッド ネオエピトープ提示のための配列の配置および配列
CA3061240C (en) 2017-04-24 2024-01-16 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
CA3086456A1 (en) 2017-12-21 2019-06-27 Kirin Holdings Kabushiki Kaisha Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) * 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
US12239699B2 (en) * 2018-09-11 2025-03-04 Shanghai Public Health Clinical Center Immunogen for broad-spectrum influenza vaccine and application thereof
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
BR112021023348A2 (pt) * 2019-05-21 2022-02-01 Esperovax Inc Vacinação oral à base de levedura
WO2021163222A1 (en) * 2020-02-11 2021-08-19 Cytonus Therapeutics, Inc. Rapid vaccine platform
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
CA3170359A1 (en) 2020-04-14 2021-10-21 Nantcell, Inc. Yeast lysate covid-19 vaccine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014876A1 (en) * 1994-11-15 1996-05-23 The Regents Of The University Of Colorado Yeast-based delivery vehicles
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20050009008A1 (en) * 2003-07-11 2005-01-13 Robinson Robin A. Functional influenza virus-like particles (VLPs)
WO2005116270A2 (en) * 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
JPH09511381A (ja) 1994-01-11 1997-11-18 ブラームス・インターユニバージテーア・インスティテュート・ボーア・ビーオテクノロジー インフルエンザワクチン
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2005284727A1 (en) 2004-09-17 2006-03-23 University Of Massachusetts Compositions and their uses for lysosomal enzyme deficiencies
CA2638815A1 (en) * 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014876A1 (en) * 1994-11-15 1996-05-23 The Regents Of The University Of Colorado Yeast-based delivery vehicles
WO2002000885A2 (en) * 2000-06-23 2002-01-03 American Cyanamid Company Assembly of wild-type and chimeric influenza virus-like particles (vlps)
WO2002039951A2 (en) * 2000-11-15 2002-05-23 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
WO2004058157A2 (en) * 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US20050009008A1 (en) * 2003-07-11 2005-01-13 Robinson Robin A. Functional influenza virus-like particles (VLPs)
WO2005116270A2 (en) * 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Okuda, K. et al. 2001 Vaccine, vol. 19, no. 27, pp. 3681-3691 *

Also Published As

Publication number Publication date
TW200806316A (en) 2008-02-01
CN101405026B (zh) 2015-04-22
IL193196A (en) 2015-01-29
BRPI0706913A2 (pt) 2011-04-12
JP2015038147A (ja) 2015-02-26
EP1988919A4 (en) 2009-06-10
KR20140029551A (ko) 2014-03-10
EP2468296A3 (en) 2013-12-04
IL232518A0 (en) 2014-06-30
SG169375A1 (en) 2011-03-30
EP2468296A2 (en) 2012-06-27
AU2007212076A1 (en) 2007-08-16
TW201412329A (zh) 2014-04-01
KR20080089671A (ko) 2008-10-07
IL193196A0 (en) 2011-08-01
US20100196411A1 (en) 2010-08-05
IN2014DN08830A (enExample) 2015-07-10
CA2638815A1 (en) 2007-08-16
US20080003239A1 (en) 2008-01-03
KR101492524B1 (ko) 2015-02-12
EP1988919A2 (en) 2008-11-12
WO2007092792A3 (en) 2008-02-28
JP2013075899A (ja) 2013-04-25
JP5198290B2 (ja) 2013-05-15
CN104826102A (zh) 2015-08-12
CN101405026A (zh) 2009-04-08
SG10201402236VA (en) 2014-08-28
JP2009528987A (ja) 2009-08-13
MX2008009929A (es) 2008-10-01
WO2007092792A2 (en) 2007-08-16
US7736642B2 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
US7736642B2 (en) Yeast-based vaccine for inducing an immune response
US8007816B2 (en) Yeast-based therapeutic for chronic hepatitis C infection
US7439042B2 (en) Yeast-based therapeutic for chronic hepatitis C infection
US10849971B2 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
CA2974346A1 (en) Novel multivalent nanoparticle-based vaccines
CA3170359A1 (en) Yeast lysate covid-19 vaccine
AU2013200249A1 (en) Yeast-based vaccine for inducing an immune response
HK1172556A (en) Yeast-based vaccine for inducing an immune response

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired